<html>
<head>
    <script language="JavaScript" src="http://code.jquery.com/jquery-1.4.4.js"></script>
    <script language="JavaScript" src="../js/pie.js"></script>
    <script language="JavaScript" src="../js/browser_adjust.js"></script>
    <script language="JavaScript" src="../js/search.js"></script>


    <script type="text/JavaScript">
    <!--

    var array = [[9.6486730149, "../topics/{product,_candidate,_development}.html", "{product,_candidate,_development}"], [5.6966016997, "../topics/{property,_intellectual,_protect}.html", "{property,_intellectual,_protect}"], [4.4037346348, "../topics/{acquisition,_growth,_future}.html", "{acquisition,_growth,_future}"], [2.714891709, "../topics/{product,_liability,_claim}.html", "{product,_liability,_claim}"], [2.687851944, "../topics/{personnel,_key,_retain}.html", "{personnel,_key,_retain}"], [2.6504253503, "../topics/{customer,_product,_revenue}.html", "{customer,_product,_revenue}"], [2.2673757097, "../topics/{stock,_price,_operating}.html", "{stock,_price,_operating}"], [2.1091179112, "../topics/{stock,_price,_share}.html", "{stock,_price,_share}"], [1.726180728, "../topics/{cost,_regulation,_environmental}.html", "{cost,_regulation,_environmental}"], [1.6989043794, "../topics/{debt,_indebtedness,_cash}.html", "{debt,_indebtedness,_cash}"], [1.6944812744, "../topics/{provision,_law,_control}.html", "{provision,_law,_control}"], [1.5685532642, "../topics/{competitive,_industry,_competition}.html", "{competitive,_industry,_competition}"], [1.5353176212, "../topics/{product,_market,_service}.html", "{product,_market,_service}"]];
    var elements = generate_pie_elements(array);
    var piec = null;
    function init() {
        browser_adjust();
        
        // create pie chart
        piec = new PieChart(elements);
        piec.initialize();

    }

    function highlight(i) {
        piec.highlight(i);
    }
    
    function unhighlight() {
        piec.unhighlight();
    }
    //-->
    </script>

    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    
    <title>1000694--3/16/2007--NOVAVAX_INC</title>

    <link href="../styling.css" rel="stylesheet" type="text/css">
</head>

<body onLoad="init()">
<div id="navigation">
<hr noshade>
<table><tr>
    <td class="navtext">Browse&nbsp;&#x25B8;</td> 
    <td class="linked"><a>Topics</a>
      <ul> 
        <li><a href="../browse/topic-list.html">List of Terms</a></li> 
        <li><a href="../browse/topic-graph.html">Term Distributions</a></li> 
        <li><a href="../browse/topic-presence.html">Relative Presence</a></li>
      </ul> 
    </td> 
    <td class="linked"><a>Documents</a>
      <ul>
        <li><a href="../browse/doc-graph.html">Topic Distributions</a></li>
      </ul> 
    </td>
    <td class="linked"><a>Terms</a>
      <ul> 
        <li><a href="../browse/term-list.html">List by Frequency</a></li> 
        <li><a href="../browse/term-graph.html">Topic Distributions</a></li> 
       </ul> 
    </td>
    <td class="linked"><a>About</a>
      <ul>
        <li><a href="http://www.cs.princeton.edu/~blei/lda-c/">LDA</a></li>
      </ul> 
    </td>
    
    </td>
    <td></td>
    <td class="searchbar"> Search&nbsp;&#x25B8;</td>
    <td class="searchbar"><input type="text" name="search" size="20" onkeypress="handleKeyPress(event)"><span onclick="doSearch()"></span>
    </td>
</tr></table>
</div>

    <div id="top"></div>

    <h1 id="header">
        <table><tr>
            <td id="title">1000694--3/16/2007--NOVAVAX_INC</td>
        </tr></table>

        <hr noshade>
    </h1>

    <div id="main">
        <table><tr>
            <td width="210px">
                <table class="dark">
                <tr><td><canvas id="canvas" width="200" height="200"></canvas></td></tr>
                <tr class="title">
                    <td>related topics</td>
                </tr>
                <tr class="list"><td id="{product,_candidate,_development}" onmouseover="highlight(0)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_candidate,_development}.html'">{product, candidate, development}</td></tr>
<tr class="list"><td id="{property,_intellectual,_protect}" onmouseover="highlight(1)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{property,_intellectual,_protect}.html'">{property, intellectual, protect}</td></tr>
<tr class="list"><td id="{acquisition,_growth,_future}" onmouseover="highlight(2)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{acquisition,_growth,_future}.html'">{acquisition, growth, future}</td></tr>
<tr class="list"><td id="{product,_liability,_claim}" onmouseover="highlight(3)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_liability,_claim}.html'">{product, liability, claim}</td></tr>
<tr class="list"><td id="{personnel,_key,_retain}" onmouseover="highlight(4)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{personnel,_key,_retain}.html'">{personnel, key, retain}</td></tr>
<tr class="list"><td id="{customer,_product,_revenue}" onmouseover="highlight(5)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{customer,_product,_revenue}.html'">{customer, product, revenue}</td></tr>
<tr class="list"><td id="{stock,_price,_operating}" onmouseover="highlight(6)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{stock,_price,_operating}.html'">{stock, price, operating}</td></tr>
<tr class="list"><td id="{stock,_price,_share}" onmouseover="highlight(7)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{stock,_price,_share}.html'">{stock, price, share}</td></tr>
<tr class="list"><td id="{cost,_regulation,_environmental}" onmouseover="highlight(8)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{cost,_regulation,_environmental}.html'">{cost, regulation, environmental}</td></tr>
<tr class="list"><td id="{debt,_indebtedness,_cash}" onmouseover="highlight(9)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{debt,_indebtedness,_cash}.html'">{debt, indebtedness, cash}</td></tr>
<tr class="list"><td id="{provision,_law,_control}" onmouseover="highlight(10)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{provision,_law,_control}.html'">{provision, law, control}</td></tr>
<tr class="list"><td id="{competitive,_industry,_competition}" onmouseover="highlight(11)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{competitive,_industry,_competition}.html'">{competitive, industry, competition}</td></tr>
<tr class="list"><td id="{product,_market,_service}" onmouseover="highlight(12)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_market,_service}.html'">{product, market, service}</td></tr>

                </table>
            </td>

            <td>
                <table class="light">
                <tr class="doc"><td>
                    We have repositioned ourselves from a specialty pharmaceutical company and face all the risks inherent in the implementation of a new business strategy.
We have limited financial resources and we are not certain that we will be able to maintain our operations or to fund the development of future products.
Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.
We may have product liability exposure.
If we lose or are unable to attract key management or other personnel, we may experience delays in product development.
We have experienced significant management turnover.
Our substantial indebtedness could adversely affect our cash flow and prevent us from fulfilling our obligations.
The conversion of our outstanding convertible debt, and the issuance of shares of our common stock upon conversion or exercise of preferred stock and/or warrants or in future offerings would cause dilution of existing security holders interests in the Company and may cause the price of our common stock to go down.
We have made loans to certain of our directors, which could have a negative impact on our stock price.
Because our product development efforts depend on new and rapidly evolving technologies, we cannot be certain that our efforts will be successful.
We have not completed the development of products other than ESTRASORB and we may not succeed in obtaining the FDA approval necessary to sell additional products.
We must identify products and product candidates for development with our technologies and establish successful third-party relationships.
Even though we have received governmental support in the past, we may not continue to receive support at the same level or at all.
If we or our collaborators are unable to manufacture our products in sufficient quantities or are unable to obtain regulatory approvals for a manufacturing facility for our products, we may experience delays, and be unable to meet demand, and may lose potential revenues.
We rely on a limited number of suppliers for some of our manufacturing materials. Any problems experienced by any of these suppliers could negatively affect our operations.
We have limited marketing capabilities, and if we are unable to enter into collaborations with marketing partners or develop our own sales and marketing capability, we may not be successful in commercializing any approved products.
If reforms in the health care industry make reimbursement for our potential products less likely, the market for our potential products will be reduced, and we will lose potential sources of revenue.
RISKS FROM COLLABORATION RELATIONSHIPS AND STRATEGIC ACQUISITIONS
The return on our investment in ESTRASORB depends in large part on the success of our relationship with Esprit Pharma, Inc. and our ability to manufacture the product.
We must utilize our manufacturing facility for products other than ESTRASORB in order to avoid operating the facility at a loss.
Our plan to use collaborations to leverage our capabilities and to grow in part through the strategic acquisition of other companies and technologies may not be successful if we are unable to integrate our partners capabilities or the acquired companies with our operations or if our partners do not meet expectations.
Our collaboration agreements may prohibit us from conducting research in areas that may compete with our collaboration products, while our collaborators may not be limited to the same extent. This could negatively affect our ability to develop products and, ultimately, prevent us from achieving a continuing source of revenues.
Because we depend on third parties to conduct some of our laboratory testing and human studies, we may encounter delays in or lose some control over our efforts to develop products.
We may fail to obtain regulatory approval for our products on a timely basis or comply with our continuing regulatory obligations after approval is obtained.
Because we are subject to environmental, health and safety laws, we may be unable to conduct our business in the most advantageous manner.
Our success depends on our ability to maintain the proprietary nature of our technology.
If we infringe or are alleged to infringe intellectual property rights of third parties, it will adversely affect our business, financial condition and results of operations.
We may become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, which could be expensive and time consuming.
We may need to license intellectual property from third parties and if our right to use the intellectual property we license is affected, our ability to develop and commercialize our product candidates may be harmed.
If patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize our discoveries.
RISKS RELATED TO OUR COMMON STOCK AND ORGANIZATIONAL STRUCTURE
Because our stock price has been and will likely continue to be volatile, the market price of our common stock may be lower or more volatile than you expected.
<p><a href="http://www.sec.gov/Archives/edgar/data/1000694/0000950133-07-001137.txt">Full 10-K form&nbsp;&#x25B8;</a></p>
                </td></tr>
                </table>
            </td>

            <td width="25%">
                <table class="dark">
                <tr class="title">
                    <td>related documents</td>
                </tr>
                <tr class="list"><td onclick="window.location.href='../docs/722104--3-16-2007--SAVIENT_PHARMACEUTICALS_INC.html'">722104--3/16/2007--SAVIENT_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/944522--3-23-2009--VION_PHARMACEUTICALS_INC.html'">944522--3/23/2009--VION_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/722104--3-14-2008--SAVIENT_PHARMACEUTICALS_INC.html'">722104--3/14/2008--SAVIENT_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/932903--3-17-2008--AVIGEN_INC_\DE.html'">932903--3/17/2008--AVIGEN_INC_\DE</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/932903--3-16-2007--AVIGEN_INC_\DE.html'">932903--3/16/2007--AVIGEN_INC_\DE</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1162192--3-31-2009--AVALON_PHARMACEUTICALS_INC.html'">1162192--3/31/2009--AVALON_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/730272--6-9-2006--REPLIGEN_CORP.html'">730272--6/9/2006--REPLIGEN_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1305409--3-20-2006--Valera_Pharmaceuticals_Inc.html'">1305409--3/20/2006--Valera_Pharmaceuticals_Inc</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/927829--3-6-2008--NITROMED_INC.html'">927829--3/6/2008--NITROMED_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/877902--3-8-2006--NEOSE_TECHNOLOGIES_INC.html'">877902--3/8/2006--NEOSE_TECHNOLOGIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/932903--3-16-2009--AVIGEN_INC_\DE.html'">932903--3/16/2009--AVIGEN_INC_\DE</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/886744--2-28-2008--GERON_CORP.html'">886744--2/28/2008--GERON_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/886744--3-16-2007--GERON_CORP.html'">886744--3/16/2007--GERON_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/899923--8-26-2009--MYRIAD_GENETICS_INC.html'">899923--8/26/2009--MYRIAD_GENETICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/899923--8-12-2010--MYRIAD_GENETICS_INC.html'">899923--8/12/2010--MYRIAD_GENETICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1029142--3-16-2007--DYNAVAX_TECHNOLOGIES_CORP.html'">1029142--3/16/2007--DYNAVAX_TECHNOLOGIES_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1029142--3-16-2006--DYNAVAX_TECHNOLOGIES_CORP.html'">1029142--3/16/2006--DYNAVAX_TECHNOLOGIES_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1066833--3-15-2006--DOV_PHARMACEUTICAL_INC.html'">1066833--3/15/2006--DOV_PHARMACEUTICAL_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/882095--2-27-2007--GILEAD_SCIENCES_INC.html'">882095--2/27/2007--GILEAD_SCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1123979--2-4-2010--SENOMYX_INC.html'">1123979--2/4/2010--SENOMYX_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/884731--3-14-2007--ARIAD_PHARMACEUTICALS_INC.html'">884731--3/14/2007--ARIAD_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/819050--3-10-2006--VICAL_INC.html'">819050--3/10/2006--VICAL_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/786623--3-27-2008--ADVANCED_VIRAL_RESEARCH_CORP.html'">786623--3/27/2008--ADVANCED_VIRAL_RESEARCH_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1068796--3-14-2007--MAXYGEN_INC.html'">1068796--3/14/2007--MAXYGEN_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/887359--9-13-2006--AASTROM_BIOSCIENCES_INC.html'">887359--9/13/2006--AASTROM_BIOSCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/914475--2-11-2008--NEUROCRINE_BIOSCIENCES_INC.html'">914475--2/11/2008--NEUROCRINE_BIOSCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1131324--3-16-2007--GENOMIC_HEALTH_INC.html'">1131324--3/16/2007--GENOMIC_HEALTH_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1476170--9-28-2010--Unilife_Corp.html'">1476170--9/28/2010--Unilife_Corp</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1033025--3-17-2006--PRAECIS_PHARMACEUTICALS_INC.html'">1033025--3/17/2006--PRAECIS_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/891293--3-16-2006--CELL_THERAPEUTICS_INC.html'">891293--3/16/2006--CELL_THERAPEUTICS_INC</td></tr>

                </table>
            </td>
        </tr></table>
    </div>

    <div id="footer">
        <br>
        <hr noshade>
    </div>
</body>
</html>
